Pages that link to "Q39637304"
Jump to navigation
Jump to search
The following pages link to Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma (Q39637304):
Displaying 29 items.
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses (Q33798326) (← links)
- Therapy-associated effects in the prostate gland (Q34115527) (← links)
- High-grade prostatic intraepithelial neoplasia (Q34291962) (← links)
- Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective (Q34304458) (← links)
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion (Q34310143) (← links)
- Human prostate cancer risk factors (Q34360616) (← links)
- Prostate changes related to therapy: with special reference to hormone therapy (Q35344149) (← links)
- Precursor lesions of prostate cancer (Q36799466) (← links)
- Pathological changes in prostate lesions after androgen manipulation (Q37215920) (← links)
- Degarelix for prostate cancer (Q37488225) (← links)
- Degarelix and its therapeutic potential in the treatment of prostate cancer (Q37510637) (← links)
- Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond (Q39586362) (← links)
- The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update (Q40403089) (← links)
- Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis (Q41094726) (← links)
- The role of neoadjuvant androgen deprivation prior to radical prostatectomy (Q41249019) (← links)
- Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer (Q42082445) (← links)
- Distinguishing Atrophy and High-Grade Prostatic Intraepithelial Neoplasia From Prostatic Adenocarcinoma With and Without Previous Adjuvant Hormone Therapy With the Aid of Cytokeratin 5/6 (Q42450444) (← links)
- Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. (Q42516157) (← links)
- Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes. (Q43125303) (← links)
- Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging (Q43666964) (← links)
- Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer (Q45864105) (← links)
- Treatment effects in prostate cancer following traditional and emerging therapies (Q46357386) (← links)
- Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy (Q47325983) (← links)
- [Therapy induced regressive changes of prostate cancer]. (Q52558636) (← links)
- Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens (Q73317310) (← links)
- Store depletion and store-operated Ca2 current in human prostate cancer LNCaP cells: involvement in apoptosis (Q74176749) (← links)
- Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes (Q74229293) (← links)
- Minimal criteria for the diagnosis of prostate cancer on needle biopsy (Q77738988) (← links)
- Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study (Q77778264) (← links)